Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

  • Tepotinib
    T61211100598-32-0
    Tepotinib (EMD-1214063) is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Cabozantinib
    T2586849217-68-1
    Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • L-Ascorbic acid 2-phosphate trisodium
    T218566170-10-3
    L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is used in biocatalytic dephosphorylation for electric power generation and electrochemical detection assays.
    • $42
    In Stock
    Size
    QTY
  • BMS817378
    T77871174161-69-3
    BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).
    • $85
    In Stock
    Size
    QTY
  • SAR125884 hydrochlorid (1116743-46-4(free base))
    T5677
    SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
    • $53
    In Stock
    Size
    QTY
  • C-Met inhibitor D9
    T67859299405-67-7
    C-Met inhibitor D9 is a c-Met kinase inhibitor.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Tepotinib hydrochloride(1 : x)
    T96011103508-80-0
    Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
    • $148
    In Stock
    Size
    QTY
  • Capmatinib xHCl
    T84161029714-89-3
    Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
    • $37
    In Stock
    Size
    QTY
  • Capmatinib 2HCl
    T42601197376-85-4
    Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. As a result, Capmatinib 2HCl potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.
    • $37
    In Stock
    Size
    QTY
  • Cabozantinib hydrochloride
    T51641817759-42-4
    Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
    • $37
    In Stock
    Size
    QTY
  • Fosgonimeton acetate
    T39507L
    Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).
    • $197
    In Stock
    Size
    QTY
  • MK-2461
    T6094917879-39-1In house
    MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an average inhibitory concentration (IC50) of 2.5 nM.
    • $54
    In Stock
    Size
    QTY
  • AMG-458
    T6378913376-83-7In house
    AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
    • $37
    In Stock
    Size
    QTY
  • Tivantinib
    T6117905854-02-6
    Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Capmatinib
    T19631029712-80-8
    Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • NVP-BVU972
    T26801185763-69-2
    NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
    • $57
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PHA-665752
    T6128477575-56-7
    PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
    • $59
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Savolitinib
    TQ02101313725-88-0
    Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
    • $42
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • NVP-TAE 226
    T1918761437-28-9
    NVP-TAE 226 (TAE226) is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Crizotinib
    T1661877399-52-5
    Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
    • $46
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PF-04217903
    T2676956905-27-4
    MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
    • $32
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SGX-523
    T22931022150-57-7
    SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Foretinib
    T3113849217-64-7
    Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Amuvatinib
    T2516850879-09-3
    Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AMG-337
    T32091173699-31-4
    AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM).
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Emibetuzumab
    T767431365287-97-3
    Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
    • $147
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Rilotumumab
    T76758872514-65-3
    Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
    • $255
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Davutamig
    T826082648058-48-2
    Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor. It functions as an antineoplastic agent [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AMG-208
    T62601002304-34-8
    AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Telisotuzumab
    T774371781223-80-0
    Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
    • $372
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Hepln-13
    T2549264369-13-7
    Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Ningetinib Tosylate
    TQ00411394820-77-9
    Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
    • $42
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • MK-8033
    TQ02191001917-37-8
    MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).
    • $98
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • MGCD-265 analog
    T6351875337-44-3
    MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.
    • $51
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BAY-474
    T79001033767-86-0
    BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe
    • $76
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 1D228
    T83433
    1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of cancer cells. This compound is applicable in researching gastric, liver, and vascular tumors [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • LMTK3-IN-1
    T776202764850-23-7
    Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway. LMTK3-IN-1 has shown anticancer activity in a variety of cancer cell lines and in vivo BC mouse models. LMTK3-IN-1 (10-20 μM) can induce the apoptosis of BC cell line.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • MET/PDGFRA-IN-1
    T78843
    MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET. It impedes MET phosphorylation, thereby promoting apoptosis, and curtails the proliferation of various MET-positive cell lines, with IC50 values of 15.3 μM for AsPc-1, 19.0 μM for EBC-1, 22.0 μM for MKN-45, 25.6 μM for Mia-Paca-2, 21.0 μM for HT-29, and 31.5 μM for K562 [1].
    • Inquiry Price
    Size
    QTY
  • c-Met-IN-18
    T78934
    C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancers [1].
    • Inquiry Price
    Size
    QTY
  • c-Met-IN-19
    T79715
    c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0.36, 0.98, and 0.76 μM, respectively [1].
    • Inquiry Price
    Size
    QTY
  • c-met-IN-1
    T106532084836-84-8
    c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
    • $1,820
    Backorder
    Size
    QTY
  • Tyrosine kinase inhibitor
    T171841021950-26-4
    Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
      7-10 days
      Inquiry
    • Dihexa
      T73761401708-83-5
      Dihexa (Hexanoyl-Tyr-Ile-Ahx-NH2) is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
      • $63
      In Stock
      Size
      QTY
    • RIPK3-IN-1
      T635442361139-70-8
      RIPK3-IN-1 is a selective and potent RIPK3 inhibitor (IC50: 9.1 nM) that inhibits the activities of c-Met kinase, RIPK1 and RIPK2.RIPK3-IN-1 has potential tumorigenic activity and can be used to study apoptosis.
      • $71
      In Stock
      Size
      QTY
    • EGFR-IN-8
      T111622407957-87-1
      EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.
      • $69
      In Stock
      Size
      QTY
    • SGI-7079
      T69821239875-86-5
      SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
      • $41
      In Stock
      Size
      QTY
    • Glesatinib
      T15384936694-12-1
      Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.
      • $1,670
      Backorder
      Size
      QTY
    • Ensartinib hydrochloride
      T223242137030-98-7
      Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM.
      • $60
      In Stock
      Size
      QTY
    • CSF1R-IN-2
      T131942271119-26-5
      CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
      • $64
      In Stock
      Size
      QTY
    • c-Met inhibitor 1
      T106551357072-61-7
      c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
      • $77
      In Stock
      Size
      QTY